Altrine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altrine

This foundational section provides a clear, high-level overview of the medication Altrine, defined by its composition and pharmacological classification, strictly excluding details on dosages, usage instructions, or safety information.

Property Description
Active Ingredient Cetirizine Hydrochloride
Form Oral tablet, caplet, and oral solution (syrup)
Pharmacological Class Second-Generation Antihistamine
Common Use General relief of allergic symptoms
Origin Synthetic, derived from Hydroxyzine

What is Altrine and What is its Role?

Altrine is a product containing the active ingredient Cetirizine Hydrochloride, primarily used to provide relief from the symptoms associated with allergic reactions. This medication is classified as a second-generation antihistamine, a designation that places it among modern anti-allergic agents. Its primary role is to counteract the effects of histamine released during the body's immune response to allergens, serving as a general mitigating agent against discomfort caused by seasonal or chronic exposure. It is clinically recognized for its role in reducing common allergy-related physical symptoms.


Composition, Origin, and Form of Altrine

The composition of Altrine is centered upon the single active compound, Cetirizine Hydrochloride, delivered via the oral route. This core component is synthetic, having been chemically developed as a key metabolite derived from the earlier pharmaceutical agent, Hydroxyzine. The synthetic origin ensures a consistent and standardized product profile. To serve a wide range of patients, particularly children, Altrine is available in several established dosage forms, including oral tablets, caplets, and an oral solution (syrup), simplifying administration for younger patient groups.


Pharmacological Class: Selective H1-Receptor Antagonism

Altrine's effectiveness is directly linked to its function as a selective peripheral histamine H1-receptor antagonist, the precise mechanism defining its pharmacological class. This means the drug works by specifically blocking the H1 receptor sites located on various peripheral cells, thereby preventing histamine from binding and triggering allergic symptoms. Unlike first-generation antihistamines, the selective nature of the H1 antagonism is a distinguishing factor, contributing to its favorable profile. This targeted mechanism achieves the general benefit of interrupting the immediate allergic cascade, which is essential for controlling the common physical manifestations of allergic episodes.

Regulatory References

  1. Cetirizine: MedlinePlus Drug Information
  2. Cetirizine - StatPearls - NCBI Bookshelf - NIH
  3. Label: CETIRIZINE HYDROCHLORIDE tablet, film coated - DailyMed - NIH

What side effects are possible with Altrine?

Possible Side Effects and Safety Information

The safety profile for Altrine (Cetirizine Hydrochloride) is officially documented by regulatory authorities, classifying possible adverse reactions primarily by frequency and the body system affected. The most frequently observed reactions are classified as Common, occurring in 1 in 10 to 1 in 100 individuals.

Adverse Reaction Classification

The most frequently listed side effects include somnolence (drowsiness), fatigue, headache, and dry mouth, which are categorized as Common. Less frequent effects, classified as Uncommon, include symptoms such as pruritus (itching) and rash. Reactions categorized as Rare or Very Rare are less common but include serious effects such as convulsions and anaphylactic shock, which is the most severe form of allergic reaction.

Regulatory documents group effects into System-Organ Classes (SOCs), which include Nervous System Disorders (e.g., dizziness, somnolence) and Gastrointestinal Disorders (e.g., nausea, abdominal pain).

Population-Specific Safety Notes

The regulatory profile specifies safety constraints for certain populations, particularly those with compromised drug clearance. Altrine is contraindicated in individuals with known hypersensitivity to the medicine or its derivatives, as well as in patients experiencing severe renal failure (creatinine clearance less than 10 mL/min). Caution is advised in older adults due to the potential for age-related decline in renal function. Furthermore, the official label notes the potential for pruritus or urticaria to occur after the discontinuation of daily, long-term use of the medication. The concurrent use of alcohol or other central nervous system depressants may also cause additional reductions in alertness, as documented in regulatory safety information.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving products containing Cetirizine Hydrochloride (Altrine) is strictly defined by documented clinical manifestations and regulator-mandated emergency actions.

Documented Manifestations and Severe Outcomes

The most frequently observed clinical sign in adult overdose cases is somnolence (drowsiness). In children, regulatory documents note an initial presentation of increased irritability or restlessness, which may precede drowsiness. Other documented symptoms include fatigue, headache, dizziness, and diarrhea.

In post-marketing experience, severe, very rare outcomes listed in official regulatory documents include neurological events such as convulsions (seizures), syncope (fainting), tremor, dystonia, and dyskinesia. Cardiac monitoring may be required in the management of large-dose exposures due to potential concern for arrhythmias.

Required Emergency Actions

Due to the risk of serious outcomes, official labeling mandates that individuals seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected. Management is defined as symptomatic and supportive treatment, as regulatory documents explicitly state that no known specific antidote is available.

A population-specific consideration noted in official documents is that the drug’s elimination half-life is prolonged in the elderly due to age-related changes in renal function, which is a factor in overdose management.

Therapeutic Uses of Altrine

Quick Facts

  • Relieves symptoms associated with seasonal allergic rhinitis (hay fever).
  • Assists in the management of perennial allergic rhinitis, which occurs year-round.
  • Aids in reducing signs and symptoms of chronic idiopathic urticaria (hives) in adults and children.

What Altrine Treats: Main Uses and Benefits

Altrine is indicated for addressing the symptoms of several allergic conditions. Its established utility is in providing relief for individuals experiencing seasonal allergic rhinitis, often referred to as hay fever. This includes assisting in the temporary mitigation of symptoms such as sneezing, runny nose (rhinorrhea), and itching of the nose and eyes.

For those with allergies persisting throughout the year, Altrine is also a suitable component in the treatment plan for perennial allergic rhinitis. The medication works to reduce the burden of these ongoing, non-seasonal symptoms.

Furthermore, Altrine is an option for the management of the uncomplicated skin manifestations associated with chronic idiopathic urticaria (hives). In this context, the medication helps to lessen the itching and redness of the skin in affected adults and pediatric patients. This medication is part of a therapeutic class designed to support the body's response to histamine-related conditions.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Altrine?

This section defines the officially documented eligibility and non-eligibility rules for Altrine (Cetirizine Hydrochloride), as stated in government regulatory labeling.


Eligibility and Exclusion Status

Category Official Regulatory Status
Absolute Contraindication Patients with known hypersensitivity to the active substance, its parent compound hydroxyzine, or any piperazine derivatives. Patients with severe renal impairment or End-Stage Renal Disease (eGFR below 15 ml/min).
Age-Group Approval Approved for use in Adults and Adolescents (ge 12 years). Approved pediatric use begins at 6 months of age for liquid formulations and specific indications.
Restricted Use Patients with moderate renal impairment require a modification of the standard regimen. Caution is recommended for patients with a predisposition to urinary retention or those at risk of convulsions (e.g., epileptic patients).
Pregnancy / Lactation Pregnancy: Use only if clearly needed and after medical advice. Lactation: Use is not recommended due to excretion of the substance into breast milk.

Population-Specific Limitations

Altrine tablet formulations are not recommended for children under six years old as they do not permit the necessary dosage adjustment. Use for solely hepatic impairment generally requires no dose modification. The official eligibility profile is strictly defined by regulatory documents based on organ function, age, and patient history.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Altrine

Interaction scope

Medicinal product categories with officially documented interactions include CNS Depressants and Methylxanthines. Specifically, Alcohol and tranquilizers are noted to have a pharmacodynamic interaction. The most significant pharmacokinetic interaction is with Theophylline (at a 400 mg daily dose), which results in a measurable reduction of Altrine clearance, leading to higher levels of Altrine in the body. Altrine exhibits minimal involvement with major liver enzyme systems; regulatory studies confirm no clinically significant interactions were observed with medications such as Ketoconazole, Erythromycin, or Azithromycin. Food intake only affects the rate, not the overall extent, of absorption, and there are no mandatory timing-separation rules for administration.

Interaction classifications (high-level)

The primary restriction is related to the additive effect of Altrine with other substances that affect the central nervous system. This is classified as an interaction requiring caution, and concurrent use with Alcohol or other CNS depressants must be avoided or limited. The official data for these constraints are derived from government documents such as the FDA Prescribing Information and European SmPC.

Official interaction statements:

  • Co-administration with Theophylline resulted in a quantifiable reduction in Altrine clearance.
  • Simultaneous consumption of Alcohol or other CNS Depressants may cause an additional reduction in alertness.
  • No clinically significant pharmacokinetic interactions were observed in studies with certain macrolides or antifungals.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is primarily defined by a pharmacodynamic additive effect with substances that cause drowsiness and a specific, quantifiable pharmacokinetic effect related to Theophylline's influence on Altrine clearance. Regulatory documentation emphasizes that most common co-administered medicines show no evidence of a clinically significant interaction.

Mechanism of Action

Selective H1 Receptor Blockade and Vascular Stabilization

Altrine (Cetirizine Hydrochloride) acts as a selective competitive antagonist with high affinity for peripheral histamine H1 receptors located on vascular cells and smooth muscle. By occupying these receptor sites, the mechanism actively prevents histamine from initiating its signaling cascade. This action results in the physiological stabilization of the blood vessel barrier's integrity, which inhibits the histamine-induced increase in vascular permeability and dampens H1-mediated nerve signal generation.

Non-Antihistaminic Anti-inflammatory Modulation

This secondary mechanistic domain modulates the subsequent cellular phase, which involves the continued mobilization of immune cells following the initial histamine release. The drug engages mechanisms that suppress the movement and accumulation (chemotaxis) of key allergic immune cells, specifically eosinophils and neutrophils, from the bloodstream into the reactive tissues. This selective interference with cellular infiltration modulates the cellular component of the immune response, contributing to the sustained adjustment of the physiological reaction pattern.

Dosage and Administration Information

How to Use Altrine: Official Administration Guidelines

Altrine (Cetirizine Hydrochloride) is typically administered via the oral route, although an intravenous (IV) formulation is approved for use in specific acute clinical settings. The medicine is primarily available in standardized oral forms, including tablets, chewable tablets, and a solution or syrup.

Dosing and Frequency Principles

The established standard maximum oral dose for adults and adolescents (age 12 and older) is 10 mg once every 24 hours. Administration is usually once daily, although some pediatric regimens (for children aged 2 to 5 years) utilize divided doses of 2.5 mg taken twice daily to reach the maximum daily limit.

Administration Conditions

Altrine may be taken with or without food, as food intake does not reduce the total amount of the drug absorbed. Oral tablets should be swallowed whole with liquid. If the oral solution or syrup is used, a calibrated dosing device must be used for accurate measurement, which is crucial for pediatric dosing. If a regular dose is missed, a double dose must not be taken to compensate.

Population-Specific Use Adjustments

Dosing regimens require official modification for patients with impaired renal function due to the drug's primary elimination pathway. For instance, the dose is typically reduced to 5 mg once daily for moderate renal impairment, and the oral formulation is often contraindicated in severe renal disease. A reduced starting dose of 5 mg once daily is also recommended for older adults if their renal function is reduced.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Altrine


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research exploring short-term changes in symptoms has used numerous controlled studies, often comparing Altrine to an inactive substance (placebo). These studies were conducted during periods of increased symptom activity and focused on adults and pediatric patients down to two years of age. Research examined outcomes related to physical discomfort, specifically tracking changes in symptoms like sneezing, itchy nose, and watery eyes using standardized measurement tools.

Studies report how symptoms were measured and characterized in the observed populations during the short trial periods. Findings describe patterns observed in studies exploring how symptom intensity was measured. A key limitation is that follow-up durations were limited. Research contributes to the broader evidence landscape but does not predict individual outcomes over many allergy seasons.


Evidence for Use in Perennial Allergic Rhinitis (PAR)

Studies exploring outcomes related to Altrine were conducted for conditions where symptoms may vary in intensity across the year. These included intermediate-duration randomized trials and comparative research involving populations with symptoms persisting year-round. Research monitored outcomes related to functional imbalance, specifically looking at changes in symptom scores over periods up to six months. The sustained patterns of observations across many years of continuous use are not fully described in controlled trial evidence, and this constitutes an area where certainty remains low.


Evidence in Special Populations and Research Gaps

Altrine was evaluated in a wide range of age groups, with specific trials focusing on pediatric patients. In contrast, dedicated data for older adults (65 years and over) remain limited. While short-term research is extensive, there is limited information for long-term outcomes related to sustained management over many years. Furthermore, evidence comparing Altrine directly against some other available pharmacological agents is limited in certain areas. Results apply only to the populations studied, and data for certain groups remain insufficient.

Key Studies & References NICE Guideline NG138: Chronic urticaria and angioedema (Summary of evidence base)

Frequently Asked Questions (FAQ)

Common questions about Altrine (FAQ)

Q: What is the main difference between Altrine and other common medicines for the same condition?

A: Altrine is officially classified as a second-generation antihistamine. This means it works by targeting and blocking peripheral H1 receptors (sites in the body where histamine acts) in a selective way. This mechanism is a key factor that differentiates it from some older antihistamines, which are often associated with a higher potential for central nervous system effects.

Q: How long does it typically take to feel any effect after starting Altrine?

A: Official product information notes that the onset of action is typically rapid. Effects may start to be noticeable within about 20 to 60 minutes after taking a dose.

Q: Is it necessary to take Altrine at the exact same time every day?

A: Official patient instructions suggest taking the medication at around the same time every day. This approach helps ensure a consistent level of the medicine is maintained in the body to achieve its general benefit.

Q: Is Altrine safe to take for an extended period, like several months?

A: Clinical trials examining the use of Altrine for chronic conditions include observation periods lasting up to six months. Official regulatory documents include a specific note that pruritus (itching) or urticaria (hives) has the potential to occur after the discontinuation of daily, long-term use of the medicine.

Q: Does Altrine interact with caffeine or energy drinks?

A: The official interaction profile of Altrine does not specifically name caffeine. However, regulatory documents suggest exercising caution regarding substances that may also affect the central nervous system (CNS) because of the medicine's primary interaction with another related substance called Theophylline.

Q: Are there any known issues with taking Altrine if I have high blood pressure?

A: Official regulatory information for Altrine (Cetirizine) as a standalone medicine does not list high blood pressure (hypertension) as a specific contraindication or a required special precaution. Official constraints related to blood pressure are typically found with certain combination products that include a decongestant.

Q: Can Altrine affect my sleep pattern?

A: According to official documents, the most common effect on the nervous system is somnolence, which is a feeling of drowsiness. Less frequent effects on sleep, such as insomnia or other sleep disturbances, have also been described in post-marketing reports.

Q: Is Altrine considered a 'new' drug, or has it been around for a while?

A: Altrine (Cetirizine) is classified as a second-generation antihistamine. It was chemically developed as a key metabolite of the older pharmaceutical agent Hydroxyzine. The medicine has been available in various regulatory-approved forms since the 1990s.

Q: Why does the packaging say Altrine is only available by prescription?

A: The regulatory status of Cetirizine Hydrochloride varies across regions. While the standard oral forms are commonly available over-the-counter (non-prescription), prescription-only status may apply to specific dosage strengths, the intravenous (IV) formulation used in clinical settings, or certain combination products.

Q: Will Altrine show up on a standard drug test?

A: Information from regulatory guidance and toxicology reports indicates that Altrine (Cetirizine) is not commonly known to cause false-positive results on standard drug screening tests, such as those that look for amphetamines or methamphetamines.

Q: Can Altrine affect the results of other lab tests?

A: Yes. Official labeling indicates that discontinuing the medicine for a specific time period is typically required before certain diagnostic procedures. This is to prevent the drug from potentially interfering with or affecting the test results.

Q: Is there a generic version of Altrine available?

A: Yes. The active ingredient in this medicine is Cetirizine Hydrochloride. This compound is widely available in generic formulations manufactured by multiple companies, as confirmed by regulatory approval data.

Q: Is there a risk of dependency or addiction with Altrine?

A: Altrine is not classified as a controlled substance and official documents do not report a risk of dependency or addiction. However, as noted in the safety profile, there is a potential for temporary reactions like itching or hives after long-term, continuous use is stopped.

Q: Can I take ibuprofen or acetaminophen while using Altrine?

A: Regulatory summaries indicate that no clinically significant pharmacokinetic interactions have been observed between Altrine and common over-the-counter medicines such as ibuprofen or acetaminophen.

Q: How long does Altrine stay in my system after the last dose?

A: The rate at which the body processes the medicine is described by its half-life. The half-life, which describes the time it takes for half of the drug to be eliminated from the body, is approximately 8 to 11 hours in adults.

Q: What kind of research is currently being done on Altrine?

A: Yes. Information regarding ongoing research studies of Altrine (Cetirizine) for various uses can be found in government-run clinical trial databases. This includes studies examining high-dose use for chronic conditions.

Q: What are the symptoms of taking too much Altrine?

A: According to official documents, symptoms of taking too much Altrine are mainly related to effects on the central nervous system (CNS). These may include drowsiness, confusion, fatigue, and headache in adults, and often agitation or irritability in children.

Q: Does Altrine make people gain or lose weight?

A: Changes in weight, including both increases and decreases, have been reported as part of post-marketing surveillance. However, the exact frequency of these effects is not known from controlled clinical trials.

Q: What information is available about Altrine and long-term liver health?

A: Post-marketing surveillance has included rare reports of abnormal liver function, such as temporary increases in liver enzymes or hepatitis. Regulatory documents note that these effects are generally reported as reversible after the medication is discontinued.

Q: Can I take Altrine with other prescribed heart medications?

A: Official regulatory information does not list a specific contraindication for the use of Altrine with common prescribed heart medications. The drug is not reported to be associated with clinically significant toxic effects on the heart when used at its recommended dosage.

Q: Is Altrine only for severe cases of the condition it treats?

A: Official information indicates that Altrine is primarily indicated for the general relief of symptoms related to both seasonal and year-round allergic rhinitis. It is also indicated for the treatment of chronic idiopathic urticaria (hives).

Q: Are there any known interactions between Altrine and herbal supplements?

A: Official guidance suggests that there is generally insufficient safety information available regarding the use of Altrine at the same time as herbal remedies or supplements. This is particularly noted for supplements that may potentially cause drowsiness or dry mouth.

Q: Can people over the age of 65 use Altrine?

A: Yes. Official regulatory documentation indicates that a reduced starting dose is generally used for older adults because of the potential for age-related decline in kidney function. Caution is officially advised for this population.

Q: If I am taking Altrine, can I still drive or operate machinery?

A: Official information suggests that users assess their individual reaction to the medication. Because Altrine can cause drowsiness and a reduction in alertness, caution is generally recommended when driving or operating machinery.

Q: What is the significance of the 'safety classification' Altrine has been given?

A: Altrine is classified as a second-generation antihistamine for systemic use. Regulatory bodies note that it is not classified as a controlled substance, which suggests a low potential for misuse or addiction.

Q: Can using Altrine make skin more sensitive to the sun?

A: Official regulatory documents do not commonly list photosensitivity, which is an increased sensitivity to sunlight, as a reported adverse effect of Altrine.

Q: If I have a chronic stomach condition, is Altrine still an option?

A: Altrine is generally tolerated by the gastrointestinal system, with common side effects including dry mouth and nausea. Official documents do not list chronic stomach conditions as a specific contraindication or a required special precaution for use.

How should Altrine be stored and disposed of?

Altrine (Cetirizine Hydrochloride) must be stored and handled according to official regulatory specifications to maintain its stability and safety. The medication requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from excess heat and moisture. The product should remain in its tightly closed, original container, and any packaging with a broken seal must not be used.

For stability, the oral solution form must be used within 6 months after opening. All forms must be stored out of the sight and reach of children. Unused or expired medication must not be disposed of in household waste or wastewater; patients should consult a pharmacist for official disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Altrine found in:

A-Z Index: